Subject(s)
Celiac Disease/epidemiology , Psoriasis/epidemiology , Adolescent , Adult , Autoantibodies/blood , Biopsy , Celiac Disease/diagnosis , Duodenum/pathology , Endoscopy , Female , GTP-Binding Proteins , Humans , Immunoglobulin A/blood , Iran/epidemiology , Male , Middle Aged , Prevalence , Protein Glutamine gamma Glutamyltransferase 2 , Psoriasis/diagnosis , Skin/pathology , Transglutaminases/immunology , Young AdultABSTRACT
AIM: To determine the prevalence of gluten sensitive enteropathy (GSE) in a large group of patients with iron deficiency anemia (IDA) of obscure origin. METHODS: In this cross-sectional study, patients with IDA of obscure origin were screened for GSE. Anti-endomysial antibody (EMA) and tissue transglutaminase antibody (tTG) levels were evaluated and duodenal biopsies were taken and scored according to the Marsh classification. The diagnosis of GSE was based on a positive serological test and abnormal duodenal histology. Gluten free diet (GFD) was advised for all the GSE patients. RESULTS: Of the 4120 IDA patients referred to our Hematology departments, 206 (95 male) patients were found to have IDA of obscure origin. Thirty out of 206 patients (14.6%) had GSE. The mean age of GSE patients was 34.6 +/- 17.03 (range 10-72 years). The female to male ratio was 1.3:1. Sixteen patients had Marsh 3, 12 had Marsh 2, and 2 had Marsh 1 lesions. The severity of anemia was in parallel with the severity of duodenal lesions. Twenty-two GSE patients (73.3%) had no gastrointestinal symptoms. Fourteen GSE patients who adhered to GFD without receiving iron supplementation agreed to undergo follow up visits. After 6 mo of GFD, their mean hemoglobin levels (Hb) increased from 9.9 +/- 1.6 to 12.8 +/- 1.0 g/dL (P < 0.01). Interestingly, in 6 out of 14 patients who had Marsh 1/2 lesions (e.g. no villous atrophy) on duodenal biopsy, mean Hb increased from 11.0 +/- 1.1 to 13.1 +/- 1.0 g/dL (P < 0.01) while they did not receive any iron supplementation. CONCLUSION: There is a high prevalence (e.g. 14.6%) of GSE in patients with IDA of obscure origin. Gluten free diet can improve anemia in GSE patients who have mild duodenal lesions without villous atrophy.
Subject(s)
Anemia, Iron-Deficiency/complications , Anemia, Iron-Deficiency/epidemiology , Celiac Disease/complications , Celiac Disease/epidemiology , Adolescent , Adult , Aged , Anemia, Iron-Deficiency/diagnosis , Antibodies/blood , Biopsy , Celiac Disease/diagnosis , Child , Cross-Sectional Studies , Duodenum/pathology , Female , Humans , Immunoglobulin A/blood , Iran/epidemiology , Male , Middle Aged , Prevalence , Prospective Studies , Sensitivity and Specificity , Severity of Illness Index , Transglutaminases/immunology , Young AdultABSTRACT
The impact of treatment on progression of fibrosis in autoimmune hepatitis (AIH) is unknown. We assessed the changes in liver fibrosis before and after treatment among these patients. Nineteen AIH patients who had paired liver biopsies were studied. Of these, seven had been treated with 6 months of cyclosporine A and the rest with 6 months of prednisolone for induction of remission. Thereafter all had been maintained on azathioprine. Biopsy specimens before and after treatment were reviewed by one pathologist and scored by the Ishak method. Mean fibrosis stages before and after treatment were compared. Also, factors predicting significant fibrosis (stage > or =3) and cirrhosis (stage > or =5) at presentation were assessed. Mean interval between biopsies was 3.38 years. Mean fibrosis stage decreased from 4.53 to 2.16 following treatment (P < 0.001). Mean decrement in inflammatory grade was 8 scores (range, 4-10) in patients in whom fibrosis improved, and 2 scores (range, 0-4) in patients in whom fibrosis did not decrease after treatment (P < 0.001). ALT-to-platelet ratio was the best predictor of significant fibrosis and also cirrhosis. Fibrosis commonly improves after immunosuppressive treatment in AIH. ALT-to-platelet ratio can predict accurately the presence of significant fibrosis and cirrhosis in AIH.
Subject(s)
Cyclosporine/therapeutic use , Hepatitis, Autoimmune/complications , Immunosuppressive Agents/therapeutic use , Liver Cirrhosis/drug therapy , Liver Cirrhosis/etiology , Prednisolone/therapeutic use , Adolescent , Adult , Analysis of Variance , Child , Cohort Studies , Disease Progression , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Hepatitis, Autoimmune/diagnosis , Humans , Liver Cirrhosis/pathology , Liver Function Tests , Logistic Models , Male , Probability , Retrospective Studies , Risk Assessment , Statistics, Nonparametric , Treatment OutcomeABSTRACT
AIM: The healthy ranges for serum alanine aminotransferase (ALT) levels are less well studied. The aim of this study was to define the upper limit of normal (ULN) for serum ALT levels, and to assess factors associated with serum ALT activity in apparently healthy blood donors. METHODS: A total of 1,939 blood donors were included. ALT measurements were performed for all cases using the same laboratory method. Healthy ranges for ALT levels were computed from the population at the lowest risk for liver disease. Univariate and multivariate analyses were performed to evaluate associations between clinical factors and ALT levels. RESULTS: Serum ALT activity was independently associated with body mass index (BMI) and male gender, but not associated with age. Association of ALT with BMI was more prominent in males than in females. Upper limit of normal for non-overweight women (BMI of less than 25) was 34 U/L, and for non-overweight men was 40 U/L. CONCLUSION: Serum ALT is strongly associated with sex and BMI. The normal range of ALT should be defined for male and female separately.
